Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019024875) USE OF SUBSTANCE DIRECTLY OR INDIRECTLY REGULATING YB-1 PHOSPHORYLATION IN PREPARATION OF DRUG FOR TREATING DISEASE CAUSED BY INFLAMMATORY FACTORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/024875 International Application No.: PCT/CN2018/098075
Publication Date: 07.02.2019 International Filing Date: 01.08.2018
IPC:
A61K 31/573 (2006.01) ,A61K 31/4375 (2006.01) ,A61K 38/19 (2006.01) ,A61P 3/04 (2006.01) ,A61P 3/10 (2006.01) ,A61P 9/10 (2006.01) ,A61P 25/08 (2006.01) ,A61P 25/28 (2006.01) ,A61P 29/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 37/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573
substituted in position 21, e.g. cortisone, dexamethasone, prednisone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
4375
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
08
Antiepileptics; Anticonvulsants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
Applicants:
吉林众泰生物技术有限公司 JILIN ZHONGTAI BIOTECHNOLOGICAL COMPANY LIMITED [CN/CN]; 中国吉林省长春市 经济技术开发区东南湖大路1055号 No. 1055 Dongnanhu Road Development Zone for Economy and Technology Changchun, Jilin 130000, CN
Inventors:
刘斌 LIU, Bin; CN
Agent:
北京海虹嘉诚知识产权代理有限公司 HAIHONG JIACHENG INTELLECTUAL PROPERTY & PARTNERS; 中国北京市 海淀区海淀南路21号中关村知识产权大厦B座9层 9th Floor, Tower B Zhongguancun Intellectual Property Mansion No. 21, South Road Haidian, Haidian District Beijing 100080, CN
Priority Data:
201710657706.903.08.2017CN
201810175137.902.03.2018CN
201810783225.717.07.2018CN
PCT/CN2018/08067527.03.2018CN
Title (EN) USE OF SUBSTANCE DIRECTLY OR INDIRECTLY REGULATING YB-1 PHOSPHORYLATION IN PREPARATION OF DRUG FOR TREATING DISEASE CAUSED BY INFLAMMATORY FACTORS
(FR) UTILISATION D'UNE SUBSTANCE RÉGULANT DIRECTEMENT OU INDIRECTEMENT LA PHOSPHORYLATION D'YB-1 DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT D'UNE MALADIE PROVOQUÉE PAR DES FACTEURS INFLAMMATOIRES
(ZH) 直接或间接调控YB-1磷酸化的物质在制备治疗炎性因子所致疾病的药物方面的应用
Abstract:
(EN) Disclosed is the use of a substance directly or indirectly regulating YB-1 phosphorylation in the preparation of a drug for treating diseases caused by inflammatory factors. The drug targets YB-1, and the active component of the drug comprises the substance directly or indirectly regulating YB-1 phosphorylation, and achieves the aim of treating diseases caused by inflammatory factors by regulating the expression level of inflammatory factors. Disclosed is a method for screening a drug for treating diseases caused by inflammatory factors.
(FR) L'invention concerne l'utilisation d'une substance régulant directement ou indirectement la phosphorylation d'YB-1 dans la préparation d'un médicament pour le traitement de maladies provoquées par des facteurs inflammatoires. Le médicament cible YB-1 et le principe actif du médicament comprend la substance régulant directement ou indirectement la phosphorylation d'YB-1 et atteint le but de traiter des maladies provoquées par des facteurs inflammatoires par régulation du niveau d'expression de facteurs inflammatoires. L'invention concerne un procédé de criblage d'un médicament pour le traitement de maladies provoquées par des facteurs inflammatoires.
(ZH) 直接或间接调控YB-1磷酸化的物质在制备治疗炎性因子所致疾病的药物方面的应用,所述药物以YB-1为靶点,且所述药物的活性成分包括直接或间接调控YB-1磷酸化的物质,并通过调控炎性因子的表达量来达到治疗炎性因子所致疾病的目的。一种治疗炎性因子所致疾病的药物的筛选方法。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)